Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial
Jazyk angličtina Země Velká Británie, Anglie Médium print
Typ dokumentu časopisecké články
Grantová podpora
BMBF
German Ministry of Education and Research
DZHK
Daiichi Sankyo Europe
633196
European Union
847770
AFNET
965286
MAESTRIA
AA/18/2/34218
British Heart Foundation - United Kingdom
German Research Foundation
01-002-2022-0118
Dutch Heart Foundation
PubMed
38591192
PubMed Central
PMC11107119
DOI
10.1093/eurheartj/ehae225
PII: 7641700
Knihovny.cz E-zdroje
- Klíčová slova
- Anticoagulation, Atrial fibrillation, Atrial high-rate episodes, Bleeding, CHA2DS2-VASc score, Device-detected atrial fibrillation, Kidney function, NOAH-AFNET 6, Stroke,
- MeSH
- antikoagulancia * aplikace a dávkování terapeutické užití MeSH
- aplikace orální MeSH
- cévní mozková příhoda prevence a kontrola epidemiologie MeSH
- fibrilace síní * farmakoterapie komplikace MeSH
- kardiovaskulární nemoci prevence a kontrola epidemiologie MeSH
- komorbidita MeSH
- lidé MeSH
- senioři MeSH
- sexuální faktory MeSH
- věkové faktory MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Atrial Fibrillation NETwork Muenster Germany
Biomedical Research Foundation Academy of Athens Greece and Hygeia Hospitals Group Athens Greece
Biostatistics Lab School of Medicine University of Crete Crete Greece
Cardiology Division European Georges Pompidou Hospital Paris France
Cardiology Unit Camposampiero Hospital AULSS Euganea Italy
Cardiovascular and Genetics Research Institute St George's University of London London UK
Centro de Investigacion Biomedica en Red Cardiovascular Madrid Spain
Department of Cardiology and Intensive Care Medicine St Vincenz Hospital Paderborn Paderborn Germany
Department of Cardiology and Internal Diseases Medical University of Gdańsk Gdańsk Poland
Department of Cardiology Heraklion University Hospital Heraklion Crete Greece
Department of Cardiology Hospital Clinic Universtitat de Barcelona Catalonia Spain
Department of Cardiology Institute for Clinical and Experimental Medicine Prague Czechia
Department of Cardiology University Hospital Antwerp Edegem Belgium
Department of Medical Science Uppsala University Uppsala Sweden
Departments of Cardiology and Physiology Maastricht University Maastricht The Netherlands
Division of Cardiology Medical University of Graz Austria
German Center for Cardiovascular Research Partner Site Hamburg Kiel Luebeck Hamburg Germany
Heart and Vascular Centre Semmelweis University Budapest Hungary
Institut d'Investigacions Biomèdiques August Pi Sunyer Barcelona Catalonia Spain
Institute of Medical Biometry and Epidemiology University Medical Centre Hamburg Eppendorf Germany
Medicine University 'Carol Davila' Colentina University Hospital Bucharest Romania
Zobrazit více v PubMed
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. . 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373–498. 10.1093/eurheartj/ehaa612 PubMed DOI
Kirchhof P, Toennis T, Goette A, Camm AJ, Diener HC, Becher N, et al. . Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med 2023;389:1167–79. 10.1056/NEJMoa2303062 PubMed DOI
Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF, et al. . Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med 2024;390:107–17. 10.1056/NEJMoa2310234 PubMed DOI
Becher N, Toennis T, Bertaglia E, Blomstrom-Lundqvist C, Brandes A, Cabanelas N, et al. . Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥ 24 h. Eur Heart J 2024;45:837–49. 10.1093/eurheartj/ehad771 DOI
McIntyre WF, Benz AP, Becher N, Healey JS, Granger CB, Rivard L, et al. . Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials. Circulation 2024;149:981–8. 10.1161/CIRCULATIONAHA.123.067512 PubMed DOI
Diederichsen SZ, Haugan KJ, Brandes A, Lanng MB, Graff C, Krieger D, et al. . Natural history of subclinical atrial fibrillation detected by implanted loop recorders. J Am Coll Cardiol 2019;74:2771–81. 10.1016/j.jacc.2019.09.050 PubMed DOI
Kaplan RM, Koehler J, Ziegler PD, Sarkar S, Zweibel S, Passman RS. Stroke risk as a function of atrial fibrillation duration and CHA2DS2-VASc score. Circulation 2019;140:1639–46. 10.1161/CIRCULATIONAHA.119.041303 PubMed DOI
Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, et al. . Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 2015;36:281–8. 10.1093/eurheartj/ehu307 PubMed DOI
Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. . Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 2020;383:1305–16. 10.1056/NEJMoa2019422 PubMed DOI
Eckardt L, Sehner S, Suling A, Borof K, Breithardt G, Crijns H, et al. . Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial. Eur Heart J 2022;43:4127–44. 10.1093/eurheartj/ehac471 PubMed DOI PMC